Pharmafile Logo
Pharmafocus logo
Advanced Search

NSCLC

Showing 15 posts of 134 posts found.

Sarah Edwards image

Breaking into the oncology market

March 10, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer, Cancer, NSCLC, edwards, gilotrif, oncology

In many ways, the US approval of Boehringer’s Gilotrif for patients with late-stage non-small cell lung cancer (NSCLC) last year …

Feature
roche_logo_shadow

Roche lung cancer drug fails

March 3, 2014
Research and Development, Sales and Marketing Cancer, MetMAb, NSCLC, Roche, Tarceva, avastin

An independent data monitoring committee has told Roche to halt a study of its experimental lung cancer drug MetMab due …

News
Alimta image

NICE rejects Alimta

February 28, 2014
Sales and Marketing Alimta, Cancer, NHS, NICE, NSCLC, lilly, pemetrexed

Eli Lilly is coming to terms with rejection by NICE after the cost watchdog said it would not recommend Alimta …

News
lilly_outside_plaque_1

Lilly drug improves lung cancer survival

February 21, 2014
Research and Development, Sales and Marketing NSCLC, lilly, necitumumab, ramucirumab

News
Roche image

Roche: NICE guidance ‘perverse’

February 4, 2014
Sales and Marketing NHS, NICE, NSCLC, Roche, Tarceva

Roche has poured scorn on NICE’s ‘perverse’ recommendation that its EGFR-TK inhibitor Tarceva should no longer be given to NHS …

News
Pfizer image

Pfizer lung cancer drug suffers late-stage setback

January 28, 2014
Research and Development, Sales and Marketing Cancer, NSCLC, Pfizer, Roche, Tarceva, dacomitinib

An experimental cancer drug developed by Pfizer has failed in two separate Phase III clinical studies. Dacomitinib is a tyrosine …

News

GSK has Tafinlar ‘breakthrough’

January 15, 2014
Sales and Marketing Cancer, FDA, GSK, NSCLC, Tafinlar

GlaxoSmithKline is on a roll, with its cancer drug Tafinlar given breakthrough therapy designation by the FDA in lung cancer …

News

New online tool to hear lung cancer patients’ stories

October 29, 2013
Medical Communications, Sales and Marketing Boehringer, NSCLC, glcc, lung cancer

The Global Lung Cancer Coalition and Boehringer Ingelheim have teamed-up to increase awareness of the challenges facing individuals and families …

News
AstraZeneca imge

AZ begins late-stage trial of new cancer drug

October 22, 2013
Research and Development, Sales and Marketing AstraZeneca, Cancer, NSCLC, selumetinib

AstraZeneca has begun a Phase III study for its investigational lung cancer pill selumetinib in patients with a genetic sub-type …

News
boehringer image

Boehringer cancer drug impresses

October 1, 2013
Research and Development, Sales and Marketing Boehringer, NSCLC, nintedanib

Boehringer Ingelheim has shown off its impressive oncology treatment nintedanib at the European Cancer Congress (ECC) in Amsterdam. The oral triple …

News
Roche image

Roche cancer treatment shows promise

September 30, 2013
Sales and Marketing MPDL3280A, Merck Serono, NSCLC, Roche

An early-stage oncology treatment has shown encouraging results in smokers with lung cancer, Roche has said in a presentation at …

News
Xalkori image

NICE: final ‘no’ for Xalkori

September 25, 2013
Sales and Marketing NICE, NSCLC, Pfizer, Xalkori

Pfizer’s worst fears have been confirmed today by NICE, which has rejected its new lung cancer drug Xalkori because of …

News
Lilly image

Phoenix from the flames for Lilly cancer drug

August 14, 2013
Research and Development, Sales and Marketing NSCLC, lilly, lung cancer, necitumumab

A drug that once looked doomed to fail has shocked analysts by helping late-stage lung cancer patients live longer. Necitumumab …

News
Boehringer image

NSCLC lift for Boehringer

June 4, 2013
Research and Development, Sales and Marketing Boehringer, NSCLC

Boehringer’s pipeline has been boosted with the news that its investigational oral triple angiokinase inhibitor nintedanib plus chemotherapy, extends the …

News

Promising signs for Novartis’ lung cancer drug

June 4, 2013
Sales and Marketing ALK+, ASCO, LDK378, NSCLC, Novartis

Targeted lung cancer treatment LDK378 has been shown to help patients with the ALK+ gene mutation in a phase I trial.Novartis’ drug …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026